In The News

Abilitech Medical, Inc | Dec 9, 2019

MN Cup Winner Abilitech Medical Secures $7.4M, Eyes FDA Approval

Learn More

410 Medical | Dec 5, 2019

410 Medical Awarded Emergency Medicine Contract with Premier

Learn More

Abilitech Medical, Inc | Dec 3, 2019

Abilitech Medical Is Winningest Startup In Minnesota, The Med Device Epicenter

Learn More

Incysus Therapeutics, Inc | Nov 26, 2019

Incysus Therapeutics to Participate in Evercore ISI HealthCONx Conference

Learn More

Azitra, Inc | Nov 21, 2019

Skin & the Microbiome – Richard Andrews, SM, MS, President/CEO and Mark Sampson, Chief Scientific Officer, of Azitra – Skin Disease, Treatment and New Technologies

Learn More

Incysus Therapeutics, Inc | Nov 21, 2019

Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

Learn More

Cognition Therapeutics, Inc. | Nov 20, 2019

Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019

Learn More

Azitra, Inc | Nov 19, 2019

Azitra Names Jeanne M. Bertonis as Chief Operating Officer

Learn More

TFF Pharmaceuticals, Inc | Nov 18, 2019

TFF Pharmaceuticals to Ring NASDAQ Stock Market Opening Bell on Wednesday, November 20, 2019

Learn More

Actuate Therapeutics | Nov 12, 2019

Actuate Therapeutics Completes $6.5 Million Series B-3 Financing To Expand Clinical Programs

Learn More

Incysus Therapeutics, Inc | Nov 7, 2019

Incysus Therapeutics to Present at the New York Oncology Investor Conference

Learn More

Cognition Therapeutics, Inc | Nov 4, 2019

Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer

Learn More

Abilitech Medical, Inc | Oct 28, 2019

Mission is Everything: An Interview with Abilitech Medical CEO Angie Conley

Learn More

| Oct 24, 2019

TFF Pharmaceuticals Prices $22 Million Public Offering of Common Stock

Learn More

410 Medical | Oct 23, 2019

Durham maker of a medical resuscitation device raises $8 million from investors

Learn More

Incysus Therapeutics, Inc | Oct 22, 2019

Incysus Therapeutics to Present at the 2019 Bio Investor Forum

Learn More

410 Medical | Oct 22, 2019

410 Medical Secures $8 Million in Series A Financing, Expands Board of Directors

Learn More

Abilitech Medical, Inc | Oct 17, 2019

Abilitech Medical wins MN Cup

Learn More

Cognition Therapeutics, Inc | Oct 15, 2019

Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting

Learn More

Azitra, Inc | Oct 15, 2019

Azitra Completes $14 Million Series A Financing

Learn More

Azitra, Inc | Oct 8, 2019

Azitra Presents Data Showing Tolerability of its Lead Product Candidate ATR-04

Learn More

Abilitech Medical, Inc | Oct 3, 2019

Spotlight: Abilitech Medical develops device for people suffering weakness or injury

Learn More

Lantern Pharma, Inc | Oct 3, 2019

Lantern Pharma partners with NCI to aid precision oncology research, treatments

Learn More

Lantern Pharma, Inc | Sep 18, 2019

Lantern Pharma CEO Panna Sharma to Showcase AI Platform at Drug Repositioning, Repurposing and Rescue Conference

Learn More

Incysus Therapeutics, Inc | Sep 10, 2019

Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit

Learn More

Immusoft | Sep 10, 2019

Immusoft To Present At The International Conference On Lymphocyte Engineering 2019

Learn More

Incysus Therapeutics, Inc | Sep 4, 2019

Incysus Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference

Learn More

Lantern Pharma, Inc | Sep 4, 2019

Lantern Pharma Chief Scientific Officer Gregory Tobin to Speak at TMED 10: Disruptive Innovation in Healthcare Conference

Learn More

Azitra, Inc | Aug 27, 2019

Azitra, Inc. Appoints Mark Sampson, Ph.D. as Chief Scientific Officer

Learn More

TFF Pharmaceuticals, Inc | Aug 26, 2019

TFF Pharmaceuticals Readies $22 Million IPO

Learn More

Lantern Pharma, Inc | Aug 17, 2019

Digital Trends Editor Jeremy Kaplan Interviews Panna Sharma

Learn More

Incysus Therapeutics, Inc | Aug 6, 2019

Incysus Therapeutics Strengthens Board of Directors With Appointment of Pharmaceutical Veteran Peter C. Brandt

Learn More

Cognition Therapeutics | Jul 24, 2019

Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China

Learn More

Immusoft | Jul 17, 2019

Immusoft Announces The Appointment Of Robert Hayes, Ph.D. As Chief Scientific Officer

Learn More

Trefoil Therapeutics, Inc | Jul 16, 2019

Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases

Learn More

Cognition Therapeutics, Inc | Jul 9, 2019

Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts

Learn More

410 Medical | Jun 20, 2019

LifeFlow Showcased at Premier Inc.’s Annual Breakthroughs Conference

Learn More

Incysus Therapeutics, Inc | Jun 19, 2019

Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology

Learn More

Lung Therapeutics, Inc | Jun 10, 2019

Lung Therapeutics, Inc. Raises $36 Million In Series C Financing To Advance Clinical Pipeline

Learn More

Cognition Therapeutics, Inc | Jun 5, 2019

Cognition Therapeutics Appoints Anthony O. Caggiano M.D., Ph.D. to the Position of Chief Medical Officer

Learn More

TFF Pharmaceuticals, Inc | May 30, 2019

TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments

Learn More

Azitra, Inc | May 16, 2019

Azitra, Inc. Expands Research and Development Team to Support Clinical Development Program

Learn More

Actuate Therapeutics | May 15, 2019

Actuate Therapeutics Completes $21.7 Million Series B Financing

Learn More

410 Medical | May 10, 2019

Faster and Easier Fluid Resuscitation with LifeFlow Next Gen

Learn More

Azitra, Inc | Apr 9, 2019

Azitra Receives Ongoing Support for its Netherton Development Program from the National Science Foundation (NSF)

Learn More

Azitra, Inc | Apr 8, 2019

Azitra Demonstrates Feasibility of Engineering the Skin Microbiome to Treat Serious Skin Conditions

Learn More

Cognition Therapeutics, Inc. | Apr 5, 2019

Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens

Learn More

Cognition Therapeutics, Inc. | Mar 26, 2019

Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors

Learn More

Azitra, Inc | Mar 1, 2019

Companies To Watch: Azitra

Learn More

| Feb 4, 2019

Lung Therapeutics, Inc. Announces New Chief Financial Officer And Board Member

Learn More

Azitra, Inc | Jan 30, 2019

Azitra’s Clinical Study of AZT-04 for Cosmetic Use Completes Enrollment

Learn More

410 Medical | Jan 29, 2019

Study Results Published in Journal of Infusion Nursing Highlight the Risk of the Push-Pull Fluid Delivery Method and the Benefit of LifeFlow, an Innovative New Device

Learn More

Immusoft | Jan 3, 2019

Immusoft Raises $20 Million In Series B Financing

Learn More

Abilitech Medical, Inc | Jan 1, 2019

Abilitech Medical: Reinvigorating Neuromuscular Conditions with Technology & Innovation

Learn More

Abilitech Medical, Inc | Jan 1, 2019

Top 10 MedTech Startup Companies 2019

Learn More

Immusoft | Oct 17, 2018

Immusoft Receives Rare Pediatric Disease Designation For Treatment Of MPS I

Learn More

| Sep 27, 2018

TFF Pharmaceuticals Receives Notice of Intention to Grant European Patent for Its Thin Film Freezing Process, Providing IP Protection in Europe until 2028

Learn More

Immusoft | Sep 5, 2018

Immusoft Receives $3.5 Million Grant To Expand Upon Its Cell Therapy Platform

Learn More

TFF Pharmaceuticals, Inc | Jul 11, 2018

TFF Pharmaceuticals Receives Notice of Allowance for New Foundational Patent Broadly Covering Novel Inhaled Dry Powder Drug Delivery Platform

Learn More

Immusoft | May 2, 2018

Immusoft Granted Orphan Drug Designation For Treatment Of Rare Childhood Disease

Learn More

Actuate Therapeutics | Jan 15, 2018

Actuate Therapeutics Submits IND Application for Treatment of Refractory Cancers

Learn More

Lung Therapeutics | Jun 6, 2017

Lung Therapeutics breathes easy with $14M series B

Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.

Learn More

Azitra, Inc | Apr 5, 2017

Azitra Raises $3.75M to Treat Skin Diseases With Supercharged Probiotics

Learn More

Trefoil Therapeutics, Inc | Mar 13, 2017

Trefoil Therapeutics Elects Benjamin F. McGraw, III, to its Board of Directors

Learn More

Encore Vision | Feb 1, 2017

Encore Vision Delivers Big Payday to Angel Investors

Big winners in Novartis AG’s acquisition of Encore Vision for $465 million are members of a network of angel investors in Fort Worth, TX, that bet $4 million on the presbyopia-correcting eye drop that Encore Vision president and CEO Bill Burns has been working on for about nine years.

Learn More

Encore Vision | Jan 27, 2017

Novartis hangs a purchase price on Fort Worth eye care startup: $465 million

Learn More

Trefoil Therapeutics, Inc | Jan 5, 2017

Trefoil Therapeutics Raises $5.2 Million Series 1 Financing

Learn More

Cognition Therapeutics | Nov 11, 2016

Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the first Alzheimer’s patient has been dosed in a Phase 1b clinical trial of CT1812 in mild to moderate Alzheimer’s disease.

Learn More

Azitra | Oct 11, 2016

Microbiome biotech joins Peter Thiel’s Breakout Labs project

The seed-stage fund Breakout Labs has added a new biotech, the skin disorder-focused Azitra, to its growing ranks of “hard science” companies.

Learn More

Encore Vision | Jul 1, 2016

Treating presbyopia with an eye drop?

Minneapolis—Topical administration of lipoic acid choline ester 1.5% (EV06, Encore Vision) shows promise as a treatment for restoring accommodation to patients with presbyopia, said Richard L. Lindstrom, MD.

Learn More

Encore Vision | Jun 14, 2016

EV06 ophthalmic solution for presbyopia improves visual outcomes in phase 1/2 study

Presbyopic patients who were treated with EV06 ophthalmic solution showed an improvement in visual outcomes in a phase 1/2 study, Encore Vision announced in a press release.

Learn More

Encore Vision | May 27, 2016

Top 100 Entrepreneur of the Year: Encore is seeing clearly to future

Encore Vision Inc.’s Bill Burns has been working on a product that could solve a problem that has plagued humans for centuries.

Now, after about a decade of work, he appears within sight of realizing that goal.

Learn More

Cognition Therapeutics | May 11, 2016

Pittsburgh Life Sciences Greenhouse Portfolio Company Cognition Therapeutics Wins Angel Capital Association’s Luis Villabos Award

PITTSBURGH, May 11, 2016 /PRNewswire/ — Pittsburgh Life Sciences Greenhouse (PLSG), Western Pennsylvania’s only pure life sciences investment firm, announced today that premier portfolio company Cognition Therapeutics (CogRx) has been honored with the Luis Villabos Award on behalf of the Angel Capital Association (ACA), one of the most prestigious angel capital industry honors in this country.

Learn More

Encore Vision | May 5, 2016

Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

FORT WORTH, Texas, May 5, 2016 /PRNewswire/ — Encore Vision, Inc., a privately-held ophthalmic pharmaceutical company, presented positive results today during the Ophthalmic Innovation Summit from their Phase I-II study evaluating the safety and efficacy of EV06 ophthalmic solution 1.5%.

Learn More

Encore Vision | May 3, 2016

Fort Worth startup gets positive results from clinical trials for eye drug

Encore Vision, a Fort Worth startup that has developed an eye-drop treatment for presbyopia, the hardening of a lens that causes the need for reading glasses, has received positive results from early-phase clinical trials.

Learn More

Cognition Therapeutics / Lung Therapeutics | Jan 13, 2016

Five of Biotech Showcase’s most interesting startups

Presenting at the J.P. Morgan Healthcare Conference may confer some level of credibility to a company – but several worthy startups are showcased each year at the neighboring Biotech Showcase.

Learn More

Encore Vision | Dec 5, 2015

Enrollment begins for phase 1/2 clinical study of topical presbyopia drug

EV06, a lipoic acid drop, is designed to reduce crystalline protein disulfide bonds, softening the lens and restoring accommodative amplitude.

Learn More
Top